Journals / Kulak Burun Boğaz İhtisas Dergisi / 2006 / Cilt: 16 - Sayı: 2

The efficacy of botulinum toxin-A in the treatment of hypersalivation in children with cerebral palsy

Serebral palsili çocuklarda hipersalivasyon tedavisinde botulinum toksin-A uygulaması

Pages
49–53
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: In selepted patients and with appropri­ate doses, ultrasound-guided BTX-A injections may improve hypersalivation in patients with CP.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: We evaluated the efficacy of botu­linum toxin A (BTX-A) injection into the sub-mandibular salivary gland to decrease hypersali­vation in children with cerebral palsy (CP).
📊
Key Findings & Data:Patients and Methods: Three children (1 girl, 2 boys; mean age 10; range 7 to 13 years) with CP received BTX-A injections.
💡
Conclusion & Impact:Conclusion: In selepted patients and with appropri­ate doses, ultrasound-guided BTX-A injections may improve hypersalivation in patients with CP.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Nöromusküler ajanlar · Botulinum toksini tip A · Ergen

Abstract

Objectives: We evaluated the efficacy of botu­linum toxin A (BTX-A) injection into the sub-mandibular salivary gland to decrease hypersali­vation in children with cerebral palsy (CP). Patients and Methods: Three children (1 girl, 2 boys; mean age 10; range 7 to 13 years) with CP received BTX-A injections. Due to hypersalivation, two patients dirtied 50 napkins and 5-6 pieces of clothes dairy, and one patient dirtied 100 napkins and 8-9 pieces of clothes. The severity of hypersalivation was assessed using the drool rating scale. Injections were performed in the submandibular gland under ultrasound localiza­tion and under local anesthesia. The amount of saliva flow at the mouth two hours after the meals and in a duration of 30 minutes was assessed seven times: before the first injection and at different intervals after injections up to 12 weeks. The dose of BTX-A was increased from 5 to 20 units per gland in two patients, while one patient received a standard dose of 20 units. At least 50% reduction in saliva secretion at the end of three months was accepted as a successful outcome. Results: Lower doses of BTX-A were not effective to provide the desired amount of reduction in saliva in two patients. However, application of 20 units resulted in a satisfactory decrease in all the patients. Conclusion: In selepted patients and with appropri­ate doses, ultrasound-guided BTX-A injections may improve hypersalivation in patients with CP.

Özet

Serebral palsili (SP) çocuklarda hipersalivas-yonu azaltmak amacıyla submandibüler tükürük be­zine botulinum toksin A (BTX-A) uygulamasının etkinliği değerlendirildi. Hastalar ve Yöntemler: Serebral palsili üç çocuğa (1 kız, 2 erkek; ort. yaş 10; dağılım 7-13) BTX-A en­jeksiyonu uygulandı. Hipersalivasyon nedeniyle hastaların ikisi günlük yaklaşık 50 adet peçete ve 5-6 defa elbise kirletirken, bir hasta günlük 100 adet peçete ve 8-9 defa elbise kirletiyordu. Hastalara sal­ya oran ölçeğine göre puan verildi. Lokal anestezi altında ultrasonografi eşliğinde submandibüler beze BTX-A enjeksiyonu yapıldı. Yemekten iki saat sonra 30 dakikalık süreyle dudaklardan taşan tükürük mik­tarı düz tüp ile yedi defa (İşlem öncesinde, işlem sonrası birinci gün ve birinci, ikinci, dördüncü, seki­zinci ve 12. haftalarda) ölçüldü. BTX-A iki hastada üç ay süreyle her bir tükürük bezine 5 ünite'den 20 ünite'ye artırılarak uygulandı. Bir hastaya 20 ünite BTX-A uygulandı. Uç ay sonunda salyada %50 azalma başarılı olarak kafcful edildi. Bulgular: Düşük dozla başlanan iki hastada tükürük miktarında %50 azalma sağlanamadı. Yirmi ünite verildikten sonra tüm hastalar için tatmin edici sonuç elde edildi. Sonuç: Uygun doz ve hasta seçimi yapıldığında, SP'li çocukların hipersalivasyonu için ultrasonografi eşliğinde BTX-A uygulanması etkili olabilir.

🔖

Cite This Article

ALATAŞ, N., YAZGAN, P., ÖZTÜRK, A., ŞAN, İ. (2006). The efficacy of botulinum toxin-A in the treatment of hypersalivation in children with cerebral palsy. Kulak Burun Boğaz İhtisas Dergisi, Cilt: 16 - Sayı: 2, 49–53. https://ajindex.com/articles/343307

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (5)

  1. Harris SR, Purdy AH. Drooling and its management in cerebral palsy. Dev Med Child Neurol 1987;29:807-ll. Jongerius PH, Rotteveel JJ, van den Hoogen F, Joosten F, van Hulst K, Gabreels FJ. Botulinum toxin A: a new option for treatment of drooling in children with cere­bral palsy. Presentation of a case series. Eur J Pediatr 2001;160:509-12.
  2. Suskind DL, Tilton A. Clinical study of botulinum-A toxin in the treatment of sialorrhea in children with cerebral palsy. Laryngoscope 2002;112:73-81.
  3. Porta M, Gamba M, Bertacchi G, Vaj P. Treatment of sialorrhoea with ultrasound guided botulinum toxin type A injection in patients with neurological disor­ ders. J Neurol Neurosurg Psychiatry 2001;70:538-40.
  4. Pal PK, Calne DB, Calne S, Tsui JK. Botulinum toxin A as treatment for drooling saliva in PD. Neurology 2000;54:244-7.
  5. Bushara KO, Park DM, Jones JC, Schutta HS. Botulinum toxin-a possible new treatment for axillary hyperhidrosis. Clin Exp Dermatol 1996;21:276-8. Bushara KO. Sialorrhea in amyotrophic lateral sclero­ sis: a hypothesis of a new treatment—botulinum toxin A injections of the parotid glands. Med Hypotheses 1997;48:337-9.